StemRIM (4599)

478.0 -3.0 (-0.62%)
Close JPY Disclaimer

StemRIM Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
45
Equity Type
ORD
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Contact Information
Address
7-7-15, Saito-Asagi Ibaraki,567-0085 Japan
Phone
81 72 648 7152
Fax
-
Top Executives
Name
Age
Since
Title
Katsuto Tamai 0 0000 Director
Katsuto Tamai 0 2022 Director
Yoichiro Shimada 0 0000 External Audit & Supervisory Board Member
Akihiro Mizukami 67 0000 External Audit & Supervisory Board Member
Yoji Kudo 0 0000 Full-Time External Audit & Supervisory Board Member
Noriko Sawai 0 2019 Independent Outside Director
Masatsune Okajima 55 2019 President, CEO & Representative Director
Tadahiro Nagai 47 2020 Independent Outside Director
Kensuke Tomita 74 2013 Executive Chairman
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles